Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Home Newsfeeds Needham Upgrades BioCryst Pharmaceuticals to Buy, Maintains $14 Price Target

Needham Upgrades BioCryst Pharmaceuticals to Buy, Maintains $14 Price Target

Needham analyst Serge Belanger upgrades BioCryst Pharmaceuticals (NASDAQ:BCRX) from Hold to Buy and maintains $14 price target.

byBenzinga Newsdesk

February 22, 2023

1 minute read

Needham analyst Serge Belanger upgrades BioCryst Pharmaceuticals (NASDAQ:BCRX) from Hold to Buy and maintains $14 price target.

Energy Fuels Secures Critical Mineral Supply Chain Via $240M Base Resources Deal

By Stjepan Kalinic

April 24, 9:18 AM

Energy Fuels, a Lakewood, Colorado-based uranium and critical minerals producer, agreed to acquire Australian junior miner Base Resources.

BSRUF

Wells Fargo Maintains Underweight on California Water Servs Gr, Raises Price Target to $61

By Benzinga Newsdesk

October 31, 7:52 AM

Wells Fargo analyst Jonathan Reeder maintains California Water Servs Gr (NYSE:CWT) with a Underweight and raises the price target from $55 to $61.

CWT

Bullish Or Bearish On The SPY? These Direxion ETFs Offer 3X Leverage

By Melanie Schaffer

January 16, 1:59 PM

The SPDR S&P 500 (NYSE: SPY) closed 0.39% higher on Friday, recapturing the 200-day simple moving average (SMA) after struggling at the level intraday<

SPXL

Recap: Nasdaq Q2 Earnings

By Benzinga Insights

July 20, 7:35 AM

Nasdaq (NASDAQ:NDAQ) reported its Q2 earnings results on Wednesday, July 20, 2022 at 07:00 AM. Here's what investors need to know about the announcement.

NDAQ

Needham Upgrades BioCryst Pharmaceuticals to Buy, Maintains $14 Price Target

Related Posts

Energy Fuels Secures Critical Mineral Supply Chain Via $240M Base Resources Deal

Wells Fargo Maintains Underweight on California Water Servs Gr, Raises Price Target to $61

Bullish Or Bearish On The SPY? These Direxion ETFs Offer 3X Leverage

Recap: Nasdaq Q2 Earnings